Preliminary experience and short-term follow-up results of treatment of wide-necked or fusiform cerebral aneurysms with a self-expanding, closed-cell, retractable stent

The Cordis Enterprise stent (Cordis Corporation; Miami, FL, USA), is a novel self-expanding, closed-cell, retractable stent with a low profile, good navigability and flexibility, which has been recently introduced into China. We retrospectively analyzed the clinical data of 84 consecutive patients who presented to our institution from December 2008 to June 2009. They had a total of 90 wide-necked or fusiform aneurysms that were treated using Enterprise stents. A total of 97 stents were implanted into the parent arteries without technical failure. A total of 14 aneurysms were stented alone, while the remaining 76 aneurysms were treated using a combination of stent and coils, resulting in complete occlusion of 43 aneurysms, a residual neck in 11 and a residual aneurysm in 22. Procedure-related complications occurred in two patients, which resulted in one procedure-related mortality. The clinical follow-up (1–7 months) results demonstrated no neurological deterioration or re-bleeding. The short-term angiographic follow-up (3–6 months) results revealed one recurrence and no in-stent stenosis. Our results suggest that the Cordis Enterprise stent is easy to manipulate, and is safe and effective in the treatment of complex intracranial aneurysms.